{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:33:24Z","timestamp":1785429204694,"version":"3.56.0"},"reference-count":38,"publisher":"American Association for Cancer Research (AACR)","issue":"5","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA283171-01A1"],"award-info":[{"award-number":["1R01CA283171-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01GM147365"],"award-info":[{"award-number":["R01GM147365"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["R6517-22"],"award-info":[{"award-number":["R6517-22"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Resistance to Bruton tyrosine kinase inhibitors is inevitable in mantle cell lymphoma (MCL). Cyclin-dependent kinase-9 (CDK9), a key regulator of oncogenic transcription, is a promising therapeutic target. In this study, we studied a selective CDK9 inhibitor, AZD4573, in MCL. Treatment with AZD4573 thwarted growth of both parental and ibrutinib-resistant MCL cell lines and primary MCL cells and downregulated expression of MYC and MCL1. However, CDK9 inhibition enhanced basal and maximal oxygen consumption rate, as well as increased production of ATP and reactive oxygen species in ibrutinib-resistant cell lines and primary MCL cells. Whereas treatment with AZD4573 led to modest prolongation of survival in an ibrutinib-resistant MCL patient-derived xenograft mouse model, accompanied by downregulation of TNF\u03b1\/NF-\u03baB and mTORC1 signaling pathways in murine splenocytes, oxidative phosphorylation (OxPhos) was upregulated, suggesting tumor metabolic reprogramming. Single-cell RNA sequencing analysis of peripheral blood mononuclear cells (PBMC) from patients treated with AZD4573 on a clinical trial demonstrated sustained downregulation of MYC targets and OxPhos in malignant B cells from a responding patient with MCL. Conversely, two refractory patients exhibited upregulation of MYC targets and OxPhos in PBMCs. OxPhos inhibitor IACS-010759 demonstrated synergy with AZD4573 in vitro. Thus, CDK9 inhibition exhibits activity in ibrutinib-resistant MCL and can be further enhanced by cotargeting of OxPhos.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Ibrutinib resistance is a challenge in MCL. Targeting CDK9 partially overcomes this resistance but results in upregulation of cell metabolism contributing to survival. Dual targeting of CDK9 and OxPhos cooperates to suppress tumor growth, providing a rationale for future exploration of combination therapies in MCL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0818","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:56:06Z","timestamp":1777406166000},"page":"1192-1205","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9844-0367","authenticated-orcid":false,"given":"Carly","family":"Roleder","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00w6g5w60","id-type":"ROR","asserted-by":"publisher"}],"name":"City of Hope National Medical Center 1 , Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7286-7303","authenticated-orcid":false,"given":"Xiaofan","family":"Zhao","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00hj8s172","id-type":"ROR","asserted-by":"publisher"}],"name":"Columbia University 2 Department of Medicine, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health & Science University 3 Department of Biomedical Engineering, , Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4578-3531","authenticated-orcid":false,"given":"Vi","family":"Lam","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00w6g5w60","id-type":"ROR","asserted-by":"publisher"}],"name":"City of Hope National Medical Center 1 , Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9153-0722","authenticated-orcid":false,"given":"Haifeng","family":"Shen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00w6g5w60","id-type":"ROR","asserted-by":"publisher"}],"name":"City of Hope National Medical Center 1 , Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5542-0289","authenticated-orcid":false,"given":"Edward C.","family":"Dominguez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00w6g5w60","id-type":"ROR","asserted-by":"publisher"}],"name":"City of Hope National Medical Center 1 , Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4021-8592","authenticated-orcid":false,"given":"Canping","family":"Chen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00hj8s172","id-type":"ROR","asserted-by":"publisher"}],"name":"Columbia University 2 Department of Medicine, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health & Science University 3 Department of Biomedical Engineering, , Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5474-8598","authenticated-orcid":false,"given":"Sonia","family":"Rodriguez-Rodriguez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00w6g5w60","id-type":"ROR","asserted-by":"publisher"}],"name":"City of Hope National Medical Center 1 , Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5028-2868","authenticated-orcid":false,"given":"Lili","family":"Wang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00hj8s172","id-type":"ROR","asserted-by":"publisher"}],"name":"Columbia University 2 Department of Medicine, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2143-9672","authenticated-orcid":false,"given":"Tycel","family":"Phillips","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00w6g5w60","id-type":"ROR","asserted-by":"publisher"}],"name":"City of Hope National Medical Center 1 , Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3364-8324","authenticated-orcid":false,"given":"Zheng","family":"Xia","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health & Science University 3 Department of Biomedical Engineering, , Portland, Oregon."},{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health & Science University 4 Knight Cancer Institute, , Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4461-0970","authenticated-orcid":false,"given":"Alexey V.","family":"Danilov","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00w6g5w60","id-type":"ROR","asserted-by":"publisher"}],"name":"City of Hope National Medical Center 1 , Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"2026052205014667800_bib1","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","article-title":"Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis","volume":"4","author":"Hill","year":"2020","journal-title":"Blood Adv"},{"key":"2026052205014667800_bib2","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1038\/s41598-024-55728-9","article-title":"B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression","volume":"14","author":"Gambino","year":"2024","journal-title":"Sci Rep"},{"key":"2026052205014667800_bib3","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO-25-00690","article-title":"Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026052205014667800_bib4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.21.01797","article-title":"Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma","volume":"40","author":"Jain","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026052205014667800_bib5","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","article-title":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"key":"2026052205014667800_bib6","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"2026052205014667800_bib7","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjh.15108","article-title":"Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects","volume":"181","author":"Hershkovitz-Rokah","year":"2018","journal-title":"Br J Haematol"},{"issue":"16_suppl","key":"2026052205014667800_bib8","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1200\/JCO.2024.42.16_suppl.7016","article-title":"Lisocabtagene maraleucel (liso-cel) in patients (pt) with R\/R mantle cell lymphoma (MCL): subgroup analyses by number of prior systemic lines of therapy (LOT) and by response to prior Bruton tyrosine kinase inhibitor (BTKi) from the TRANSCEND NHL 001 MCL cohort (TRANSCEND-MCL)","volume":"42","author":"Palomba","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026052205014667800_bib9","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"key":"2026052205014667800_bib10","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1128\/MCB.20.8.2629-2634.2000","article-title":"P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II","volume":"20","author":"Price","year":"2000","journal-title":"Mol Cell Biol"},{"key":"2026052205014667800_bib11","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1535-7163.MCT-18-1023","article-title":"Cyclin-dependent kinase-9 is a therapeutic target in MYC-expressing diffuse large B-cell lymphoma","volume":"18","author":"Hashiguchi","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"2026052205014667800_bib12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12943-023-01762-6","article-title":"CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma","volume":"22","author":"Thieme","year":"2023","journal-title":"Mol Cancer"},{"key":"2026052205014667800_bib13","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3324\/haematol.2017.170571","article-title":"SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia","volume":"102","author":"Paiva","year":"2017","journal-title":"Haematologica"},{"key":"2026052205014667800_bib14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat Genet"},{"key":"2026052205014667800_bib15","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026052205014667800_bib16","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"2026052205014667800_bib17","article-title":"Dimensionality reduction for visualizing single-cell data using UMAP","author":"Becht","year":"2018  3","journal-title":"Nat Biotechnol"},{"key":"2026052205014667800_bib18","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"2026052205014667800_bib19","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41419-022-04684-1","article-title":"Dual BTK\/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma","volume":"13","author":"Thieme","year":"2022","journal-title":"Cell Death Dis"},{"key":"2026052205014667800_bib20","doi-asserted-by":"crossref","first-page":"eaau1167","DOI":"10.1126\/scitranslmed.aau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci Transl Med"},{"key":"2026052205014667800_bib21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","article-title":"Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials","volume":"29","author":"Yap","year":"2023","journal-title":"Nat Med"},{"key":"2026052205014667800_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13045-023-01496-4","article-title":"Beyond Bruton\u2019s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody\u2013drug conjugates, CAR T-cells, and novel agents","volume":"16","author":"Jain","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2026052205014667800_bib23","first-page":"1171","article-title":"MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53\/p53 \u2013 a Nordic Lymphoma Group study","volume":"109","author":"Rodrigues","year":"2024","journal-title":"Haematologica"},{"key":"2026052205014667800_bib24","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1182\/bloodadvances.2018016048","article-title":"Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma","volume":"2","author":"Lee","year":"2018","journal-title":"Blood Adv"},{"key":"2026052205014667800_bib25","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1158\/1078-0432.CCR-12-2170","article-title":"Inhibition of NF-\u03baB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells","volume":"19","author":"Cosimo","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026052205014667800_bib26","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","article-title":"Pathogenic role of B-cell receptor signaling and canonical NF-\u03baB activation in mantle cell lymphoma","volume":"128","author":"Saba","year":"2016","journal-title":"Blood"},{"key":"2026052205014667800_bib27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"key":"2026052205014667800_bib28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med"},{"key":"2026052205014667800_bib29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood.V124.21.78.78","article-title":"Mutational analysis of patients with primary resistance to single-agent ibrutinib in relapsed or refractory mantle cell lymphoma (MCL)","volume":"124","author":"Balasubramanian","year":"2014","journal-title":"Blood"},{"key":"2026052205014667800_bib30","doi-asserted-by":"crossref","first-page":"e165694","DOI":"10.1172\/JCI165694","article-title":"Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma","volume":"133","author":"Jiang","year":"2023","journal-title":"J Clin Invest"},{"key":"2026052205014667800_bib31","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/modpathol.2017.58","article-title":"Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms","volume":"30","author":"Onaindia","year":"2017","journal-title":"Mod Pathol"},{"key":"2026052205014667800_bib32","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41392-020-00235-2","article-title":"Regulation of cancer cell metabolism: oncogenic MYC in the driver\u2019s seat","volume":"5","author":"Dong","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"2026052205014667800_bib33","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1158\/2159-8290.CD-15-0507","article-title":"MYC, metabolism, and cancer","volume":"5","author":"Stine","year":"2015","journal-title":"Cancer Discov"},{"key":"2026052205014667800_bib34","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/s43018-021-00216-6","article-title":"Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia","volume":"2","author":"Lu","year":"2021","journal-title":"Nat Cancer"},{"key":"2026052205014667800_bib35","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccr.2012.08.014","article-title":"Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma","volume":"22","author":"Caro","year":"2012","journal-title":"Cancer Cell"},{"key":"2026052205014667800_bib36","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1002\/ijc.29934","article-title":"Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma are highly dependent on oxidative phosphorylation","volume":"138","author":"Birkenmeier","year":"2016","journal-title":"Int J Cancer"},{"key":"2026052205014667800_bib37","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.cmet.2017.10.013","article-title":"Resistance is futile: targeting mitochondrial energetics and metabolism to overcome drug resistance in cancer treatment","volume":"26","author":"Bosc","year":"2017","journal-title":"Cell Metab"},{"key":"2026052205014667800_bib38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ijc.32616","article-title":"Oxidative phosphorylation as a potential therapeutic target for cancer therapy","volume":"146","author":"Sica","year":"2020","journal-title":"Int J Cancer"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0818\/3784451\/crc-25-0818.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/5\/1192\/3796606\/crc-25-0818.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/5\/1192\/3796606\/crc-25-0818.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:01:58Z","timestamp":1779440518000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/5\/1192\/785363\/Cyclin-Dependent-Kinase-9-and-Oxidative"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0818","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8541993","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.32702139","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702136","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702169","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702148","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702154","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702142","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702178","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702166","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702160","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702193","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702163","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702151","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702184","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702190","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702181","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}